GLAST Paves the Way for the Next Generation of Cell & Gene Therapeutics and Aims to Make Them More Affordable.

We are delighted to announce that our research and development project GLAST has been officially approved for funding.

GLAST means: Granular Lyophilisation of ATMP and Subcellar Therapeutics

We are developing the next generation of Cell & Gene Therapeutics (CGTs) as true off-the-shelf products: a free-flowing dry formulation of therapeutic exosomes, cellular organelles, and living cells that can be stored and transported for years without refrigeration.

CGTs are widely regarded as one of the most promising medical innovations of our time. They offer novel treatment options for cancer, autoimmune diseases, rare genetic disorders, and regenerative medicine. Despite their enormous potential, many of these Therapeutics are currently limited by complex cold-chain requirements, high logistics costs, and restricted shelf life.

With GLAST, we aim to address these challenges. Our goal is to transform therapeutic exosomes, organelles, and cells into stable dry formulations while preserving their biological functionality. This would significantly simplify storage, transportation, and clinical application.

Particularly promising are:

• Therapeutic exosomes, natural nanovesicles that transport bioactive molecules between cells and are increasingly being explored as powerful cell-free therapeutics.
• Subcellular organelles, such as mitochondria, whose therapeutic transfer is opening new opportunities in regenerative medicine and the treatment of mitochondrial dysfunctions.
• Allogeneic cell therapeutics, including NK cells and CAR-T cells, which can be manufactured at scale and made readily available, unlike patient-specific autologous approaches.

We believe that this technology can help overcome the so-called “Valley of Death” in the CGT market. By drastically simplifying manufacturing, storage, and distribution, we anticipate cost reductions of a factor of 10 to 100, enabling broader patient access to innovative therapies worldwide.

For the upcoming proof-of-concept phase, we are seeking partners willing to provide therapeutic exosomes or allogeneic cells, such as NK cells or CAR-T cells.

If you are interested in collaborating with us, we would be pleased to hear from you. You can meet me at the Saxon Innovation Conference on June 17, 2026, at Booth 8.

We look forward to shaping the future of shelf-stable cell and gene therapeutics together.

contact: holger.reinsch@ilkdresden.de